Nasdaq:US$20.09 (-0.08) | HKEX:HK$31.40 (-0.65) | AIM:£3.14 (-0.1)
上一篇文章   |   下一篇文章
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2014-10-07

Drug R&D Update Briefing for Analysts and Investors on 17 October 2014

Press Release – 

London: Tuesday, 7 October 2014:  Chi-Med today announces that it will host a briefing to update analysts and investors on Hutchison MediPharma Limited (“HMP”), its majority owned pharmaceutical R&D division, in London on 17 October 2014. HMP has a substantial pipeline of oral, small molecule and botanical drugs for cancer and inflammatory diseases that has grown and progressed significantly in recent years.

HMP’s current clinical pipeline includes: fruquintinib, sulfatinib, epitinib, theliatinib, and AZD6094 (formerly known as volitinib), each of which has the potential to treat a number of cancers. The clinical pipeline also includes HMPL‑523 and HMPL‑004, which have potential to treat certain inflammatory conditions.  The briefing will focus on this pipeline.

During the briefing, the management team will detail the key aspects of HMP’s R&D strategy and focus, as well as providing further information on some of HMP’s pre-clinical research programmes, including its PI3Kδ inhibitor and its FGFR inhibitor.

The briefing will begin with a keynote presentation from Dr Andrew Mortlock, Vice President of Cancer Research and Development Projects of AstraZeneca, entitled, “Next Generation Kinase Inhibitors for the Treatment of Cancer.”  He is responsible for AstraZeneca’s small molecule oncology projects from lead optimization to the end of Phase IIb.

Dr Weiguo Su, Executive Vice President and Chief Scientific Officer of HMP and Dr Ye Hua, Senior Vice President of Clinical Development & Regulatory Affairs of HMP, will be presenting on HMP’s compounds in research & development and HMP’s overall strategy.

Dr Su has 24 years of experience in delivering high quality new drug candidates at HMP and at Pfizer, where he was Director of Medicinal Chemistry.  Dr Su has built HMP’s highly productive research platform, including managing the discovery of all its small molecule drug candidates.

Dr Hua has over 15 years of new drug development and registration experience, as well as many years of experience in cancer epidemiology.  In the course of his career he has led several clinical teams in pursuing registration clinical trials and achieving regulatory approval for major marketed pharmaceuticals at Novartis and Celgene.

Mr Christian Hogg, Chief Executive Officer of Chi-Med, will also give presentations covering Chi-Med’s overall business strategy and approach to funding its R&D.

No new material trading or financial information will be disseminated at the meeting.  Following the meeting, the presentations will be made available at

The briefing will take place at the Andaz Hotel, 40 Liverpool Street, London, EC2M 7QN on 17 October 2014 at 9:30am, with registration starting from 9:15am.  Please contact Mrs Janine Chase by email at to register.





Christian Hogg, CEO
Telephone:      +852 2121 8200
Panmure Gordon (UK) Limited
Richard Gray
Andrew Potts
Telephone:      +44 20 7886 2500
Citigate Dewe Rogerson
Anthony Carlisle
David Dible
Telephone:      +44 20 7638 9571
Mobile:            +44 7973 611 888
Mobile:            +44 7967 566 919


Notes to Editors

About HMP

HMP is a novel drug R&D division focusing on discovering, developing and commercialising innovative therapeutics in oncology and autoimmune diseases.  With a team of around 200 scientists and staff, its pipeline is comprised of novel oral compounds for cancer and inflammation in development in North America, Europe, Australia and Greater China.

HMP is majority owned by Chi-Med.  For more information, please visit:


About Chi-Med

Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products.  Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China.  Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases.  Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

Chi-Med is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13).  For more information, please visit: